| Field | Specification |
|---|---|
| Target | |
| Antigen | |
| Alternative names | 422 protein; Cardiac FABP; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; Fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3; muscle and heart (mammary derived growth inhibitor); Fatty acid binding protein 3; muscle; Fatty acid binding protein heart; Fatty acid binding protein; heart; Fatty acid binding protein; muscle and heart; Fatty acid binding protein; skeletal muscle; Fatty acid-binding protein 3; Fatty acid-binding protein; H FABP; H-FABP; heart; Heart type fatty acid binding protein; Heart-type fatty acid-binding protein; M FABP; M-FABP; Mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; Muscle fatty acid binding protein; Muscle fatty acid-binding protein; Mylein protein P2 homolog; O FABP; OTTHUMP00000003898; P2 adopocyte protein |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Synthetic peptide of Human FABP3 |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Primary AntibodyThis antibody targets FABP3 and was raised against a recombinant protein immunogen.
Validated Applications
| Application | Recommended Dilution |
|---|---|
| ELISA | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
| Western Blot (WB) | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
| Immunohistochemistry (IHC) | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
Antibody Specifications
| Target | FABP3 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen / Immunogen | Synthetic peptide of Human FABP3 |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 0.05% sodium azide, 40% glycerol, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Alternative Names
422 protein; Cardiac FABP; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; Fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3; muscle and heart (mammary derived growth inhibitor); Fatty acid binding protein 3; muscle; Fatty acid binding protein heart; Fatty acid binding protein; heart; Fatty acid binding protein; muscle and heart; Fatty acid binding protein; skeletal muscle; Fatty acid-binding protein 3; Fatty acid-binding protein; H FABP; H-FABP; heart; Heart type fatty acid binding protein; Heart-type fatty acid-binding protein; M FABP; M-FABP; Mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; Muscle fatty acid binding protein; Muscle fatty acid-binding protein; Mylein protein P2 homolog; O FABP; OTTHUMP00000003898; P2 adopocyte protein
Safety & Handling
| Target | FABP3 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen/Immunogen | Synthetic peptide of Human FABP3 |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 0.05% sodium azide, 40% glycerol, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Dilutions are starting recommendations. Titration is advised for each system.
| Application | Recommended Dilution |
|---|---|
| ELISA | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
| Western Blot (WB) | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
| Immunohistochemistry (IHC) | ELISA:1:1000-1:10000, WB:1:200-1:1000, IHC:1:20-1:100 |
Immunogen: Synthetic peptide of Human FABP3
Antigen Species: Human
Alternative Names
422 protein; Cardiac FABP; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_HUMAN; Fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3; muscle and heart (mammary derived growth inhibitor); Fatty acid binding protein 3; muscle; Fatty acid binding protein heart; Fatty acid binding protein; heart; Fatty acid binding protein; muscle and heart; Fatty acid binding protein; skeletal muscle; Fatty acid-binding protein 3; Fatty acid-binding protein; H FABP; H-FABP; heart; Heart type fatty acid binding protein; Heart-type fatty acid-binding protein; M FABP; M-FABP; Mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; Muscle fatty acid binding protein; Muscle fatty acid-binding protein; Mylein protein P2 homolog; O FABP; OTTHUMP00000003898; P2 adopocyte protein
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
